Violeta Jardin: The Missing Link in TXA Use for Postpartum Hemorrhage
Violeta Jardin, General Manager at Haemoview Diagnostics, shared a post on LinkedIn:
”New from the SafePartum Maternal Safety Collaborative: an Expert Review Statement on TXA in obstetric hemorrhage via Vibha Mahendra — and it asks the question protocols often skip: which patients actually benefit?
The physiology is the key: TXA blocks the fibrin-dependent tPA route of plasmin generation, so it’s most rational in hyperfibrinolytic hemorrhage.
In dilutional coagulopathy it does nothing — you need fibrinogen, plasma, platelets. In consumptive coagulopathy it can worsen microvascular thrombosis. And benefit disappears (harm becomes possible) beyond the 3-hour window from birth.
The missing piece for bedside teams is phenotyping in real time, inside that window.
That’s exactly the gap APIRO Diagnostics Kft. TPA assay® closes — a whole-blood, tPA-challenged fibrinolysis read-out that flags hyperfibrinolysis at the bedside, so TXA is targeted to the patients who will actually respond, not given empirically.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments